ClinicalTrials.gg
RecruitingNCT07508319Updated Apr 2, 2026

Role of the Immune System in Preventing Laryngeal Cancer

An observational study in Head & Neck Cancer, sponsored by European Institute of Oncology. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by European Institute of Oncology · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Head and Neck Neoplasms with a site in Italy — 42 open to participants now, 56 under way, 6 of them phase 3. Head and Neck Neoplasms · Italy.

Planned enrollment
36th of 37
3 · median 200
Started
2025
with 11 others
Observational
37 of 134
24 open now
Primary completion
2026-12
later than 24 of 55 live
Registered
130th of 134
by date
Lead sponsor
8 of 134
European Institute of Oncology

Among the 134 studies in Head and Neck Neoplasms with a site in Italy, this one is the 36th largest by planned enrollment of the 37 observational ones that give a count, is one of 12 that started in 2025, is one of 37 observational ones, reaches primary completion later than 24 of the 55 other live ones, and was the 130th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

42 of the 134 studies in Head and Neck Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Head and Neck Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation

Read the detailed description

Evaluate the immune population of TILs in LDy lesions with a high or low risk of malignant transformation. Analyze gene expression profiles in LDy lesions categorized by their risk of malignant progression.

03

Conditions studied

  • Head & Neck Cancer

Keywords

  • Laryngeal dysplasia
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study will recruit 150 consecutive, untreated LDy patients, potentially within a multicenter framework.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathological diagnosis of laryngeal dysplasia.
  • Age >18 years and .

Exclusion criteria

Exclusion Criteria:

  • Prior surgical, radiotherapeutic, or oncologic treatments for head and neck regions.
  • Congenital or acquired immunodeficiency disorders.
  • Synchronous .
  • therapy.
  • Age \<18 years or absence of research consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. differences in TILs counts

    detection of differences in TILs counts from Laryngeal dysplasia to progression to carcinoma

    Time frame: 2 years

Secondary outcomes

  1. Differences in TILs counts in LDy lesions

    Detection of Differences in TILs counts in LDy lesions categorized by their risk of malignant progression

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 216 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 13 months is below that.

Counting every sponsor, half of 238 studies reached it within 69 months; a quarter within 29 and three quarters within 144.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Apr 2, 2026
StartActual
Nov 19, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07508319
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Nov 19, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 2, 2026

Study contacts

Marta Tagliabue, MD
Contact
marta.tagliabue@ieo.it
00390257489405
francesca lombardi
Contact
francesca.lombardi@ieo.it
00390257489425
Marta Tagliabue, MD
principal investigator · Istituto Europeo di Oncologia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion